Table 3.
Clinical outcomes, n (%)
|
Clinical outcomes
|
All
|
Pathology
|
P
value
|
|
|
STEMI
|
NSTEMI
|
|||
| Efficacy endpoint | ||||
| In-hospital mortality | 6/105 (5.7) | 3/37 (8.1) | 3/68 (4.4) | 0.702 |
| 1-year MACEs1 | 7/90 (7.8) | 4/32 (12.5) | 3/58 (5.2) | 0.457 |
| Ischemic stroke | 1/90 (1.1) | 0/32 | 1/58 (1.7) | - |
| Cardiovascular death | 3/90 (3.3) | 2/32 (6.3) | 1/58 (1.7) | - |
| Myocardial infarction | 3/90 (3.3) | 2/32 (6.3) | 1/58 (1.7) | - |
| 1-year non-cardiovascular death | 11/90 (12.2) | 6/32 (18.8) | 5/58 (8.6) | 0.369 |
| Safety endpoint | ||||
| In-hospital minor bleeding | 2/105 (1.9) | 0/37 | 2/68 (2.9) | 0.834 |
| In-hospital major bleeding | 1/105 (1.0) | 0/37 | 1/68 (1.5) | 0.999 |
| Minor bleeding after discharge1 | 9/90 (10) | 3/32 (9.4) | 6/58 (10.3) | 0.999 |
| Major bleeding after discharge1 | 2/90 (2.2) | 0/32 | 2/58 (3.4) | 0.846 |
1
1-year MACE and after-discharge bleeding events percentages refer to 90 patients (9 patients were lost to follow-up and 6 patients died during hospitalization). STEMI: ST-elevation myocardial infarction; NSTEMI: Non-ST-elevation myocardial infarction; MACEs: Major adverse cardiovascular events.